Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

G Saunders

Showing results (161-170 of 169) with videos related to

Pageof 17
Sort By:
You have reached the last page of results.This site can display upto 169 results.
Lancet (London, England)|August 19, 2014
Safety and tolerability of chikungunya virus-like particle vaccine in healthy adults: a phase 1 dose-escalation trialLee-Jah Chang, Kimberly A Dowd, Floreliz H Mendoza, et al.
Clinical and Experimental Immunology|September 3, 2015
Safety, pharmacokinetics and neutralization of the broadly neutralizing HIV-1 human monoclonal antibody VRC01 in healthy adultsJ E Ledgerwood, E E Coates, G Yamshchikov, et al.
Plos Medicine|January 25, 2018
Safety and pharmacokinetics of the Fc-modified HIV-1 human monoclonal antibody VRC01LS: A Phase 1 open-label clinical trial in healthy adultsMartin R Gaudinski, Emily E Coates, Katherine V Houser, et al.
Lancet (London, England)|December 9, 2017
Safety, tolerability, and immunogenicity of two Zika virus DNA vaccine candidates in healthy adults: randomised, open-label, phase 1 clinical trialsMartin R Gaudinski, Katherine V Houser, Kaitlyn M Morabito, et al.
Proceedings of the National Academy of Sciences of the United States of America|February 23, 2017
Attenuated PfSPZ Vaccine induces strain-transcending T cells and durable protection against heterologous controlled human malaria infectionKirsten E Lyke, Andrew S Ishizuka, Andrea A Berry, et al.
Science (New York, N.Y.)|August 10, 2013
Protection against malaria by intravenous immunization with a nonreplicating sporozoite vaccineRobert A Seder, Lee-Jah Chang, Mary E Enama, et al.
The Lancet. Infectious Diseases|August 6, 2023
Safety, tolerability, and immunogenicity of the Ebola Sudan chimpanzee adenovirus vector vaccine (cAd3-EBO S) in healthy Ugandan adults: a phase 1, open-label, dose-escalation clinical trialBetty Mwesigwa, Katherine V Houser, Amelia R Hofstetter, et al.
Nature Medicine|June 9, 2016
Corrigendum: Protection against malaria at 1 year and immune correlates following PfSPZ vaccinationAndrew S Ishizuka, Kirsten E Lyke, Adam DeZure, et al.
Nature Medicine|May 10, 2016
Protection against malaria at 1 year and immune correlates following PfSPZ vaccinationAndrew S Ishizuka, Kirsten E Lyke, Adam DeZure, et al.
Pageof 17

Showing results (161-170 of 169) with videos related to

Sort By:
Pageof 17
You have reached the last page of results.This site can display upto 169 results.
Lancet (London, England)|August 19, 2014
Safety and tolerability of chikungunya virus-like particle vaccine in healthy adults: a phase 1 dose-escalation trialLee-Jah Chang, Kimberly A Dowd, Floreliz H Mendoza, et al.
Clinical and Experimental Immunology|September 3, 2015
Safety, pharmacokinetics and neutralization of the broadly neutralizing HIV-1 human monoclonal antibody VRC01 in healthy adultsJ E Ledgerwood, E E Coates, G Yamshchikov, et al.
Plos Medicine|January 25, 2018
Safety and pharmacokinetics of the Fc-modified HIV-1 human monoclonal antibody VRC01LS: A Phase 1 open-label clinical trial in healthy adultsMartin R Gaudinski, Emily E Coates, Katherine V Houser, et al.
Lancet (London, England)|December 9, 2017
Safety, tolerability, and immunogenicity of two Zika virus DNA vaccine candidates in healthy adults: randomised, open-label, phase 1 clinical trialsMartin R Gaudinski, Katherine V Houser, Kaitlyn M Morabito, et al.
Proceedings of the National Academy of Sciences of the United States of America|February 23, 2017
Attenuated PfSPZ Vaccine induces strain-transcending T cells and durable protection against heterologous controlled human malaria infectionKirsten E Lyke, Andrew S Ishizuka, Andrea A Berry, et al.
Science (New York, N.Y.)|August 10, 2013
Protection against malaria by intravenous immunization with a nonreplicating sporozoite vaccineRobert A Seder, Lee-Jah Chang, Mary E Enama, et al.
The Lancet. Infectious Diseases|August 6, 2023
Safety, tolerability, and immunogenicity of the Ebola Sudan chimpanzee adenovirus vector vaccine (cAd3-EBO S) in healthy Ugandan adults: a phase 1, open-label, dose-escalation clinical trialBetty Mwesigwa, Katherine V Houser, Amelia R Hofstetter, et al.
Nature Medicine|June 9, 2016
Corrigendum: Protection against malaria at 1 year and immune correlates following PfSPZ vaccinationAndrew S Ishizuka, Kirsten E Lyke, Adam DeZure, et al.
Nature Medicine|May 10, 2016
Protection against malaria at 1 year and immune correlates following PfSPZ vaccinationAndrew S Ishizuka, Kirsten E Lyke, Adam DeZure, et al.
Pageof 17